A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)
NCT03421197
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
426
Enrollment
INDUSTRY
Sponsor class
Conditions
Psoriasis
Interventions
DRUG:
PPC-06 400 mg QD
DRUG:
PPC-06 400 mg BID
DRUG:
PPC-06 600 mg
DRUG:
Placebo
Sponsor
Dr. Reddy's Laboratories Limited